Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Market Cap $16.51M
!
Reach your audience today.

Corporate Spotlight
Last update - 16.10pm 17/08/2026 (20 minute delay)
?
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | 0.8¢ | Day High | 0.8¢ | Day Low | 0.7¢ | |||
| Daily Volume | 2338320 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 0 | 0.7¢ | 38498300 | 0 | 0.8¢ | 18371164 | |
Directors & Senior Management
| Mr. Adrian Christopher Griffin | Chief Executive Officer, Managing Director, Director |
| Ms. Catherine Grant-Edwards | Joint Company Secretary |
| Daniel Castro | Chief Commercial Officer |
| Ms. Julie Coleman | Chief People Officer |
| Ms. Kristie Peta Young | Independent Non-Executive Director |
| Ms. Melissa Kate Chapman | Joint Company Secretary |
| Mr. Philip Andrew Thick | Independent Non-Executive Director |
| Mr. Phillip Ashley Campbell | Independent Non-Executive Chair |
| Mr. Simon Linge | President of ABRI, CEO, MD & Director |
| Steven Marshall | Chief Operating Officer |
| Mr. Stuart Tarrant | Chief Financial Officer |
Data source: ADVFN
